CollPlant is building on its progress in 2016 by increasing its distribution of VergenixFG and actively pursuing potential partnerships for its earlier-stage rhCollagen technology BioInk for 3D printing of organs and tissues. We forecast the need for a fund-raising this year and management indicated in the Q1 results that it believes it has sufficient funds into Q317. We have slightly increased our rNPV to $70m (NIS248m) as a result of rolling our model forward and using the Q1 cash position.
Written by
CollPlant Holdings |
Continuing to build on 2016 |
Q1 results |
Pharma & biotech |
5 June 2017 |
Share price performance
Business description
Next events
Analyst
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
CollPlant is building on its progress in 2016 by increasing its distribution of VergenixFG and actively pursuing potential partnerships for its earlier-stage rhCollagen technology BioInk for 3D printing of organs and tissues. We forecast the need for a fund-raising this year and management indicated in the Q1 results that it believes it has sufficient funds into Q317. We have slightly increased our rNPV to $70m (NIS248m) as a result of rolling our model forward and using the Q1 cash position.
Year end |
Revenue (NISm) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/15 |
0.0 |
(18.7) |
(22.03) |
0.0 |
N/A |
N/A |
12/16 |
0.3 |
(27.9) |
(27.72) |
0.0 |
N/A |
N/A |
12/17e |
1.3 |
(16.3) |
(12.72) |
0.0 |
N/A |
N/A |
12/18e |
2.9 |
(17.8) |
(13.86) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Commercialisation of its first products progressing
In Q1 CollPlant continued to progress commercialisation of VergenixSTR in EMEA (via its partnership with Arthrex) and VergenixFG in Europe. Following the end of the quarter it announced that it had expanded its distributor footprint in Europe with the signing of a distribution agreement in Turkey for its wound healing product, VergenixFG. The company has indicated that it intends to continue to work towards signing additional distribution agreements in further territories in Europe. Demonstrating successful traction of VergenixSTR and VergenixFG in Europe is a key factor for CollPlant in 2017. Early traction would underpin the products’ potential and therefore our forecasts, and would also start to validate the underlying technology, rhCollagen.
Earlier-stage applications becoming a focus
CollPlant has indicated that it is actively pursuing potential joint ventures to develop its biological ink (BioInk) for the production of 3D scaffolds. The company has indicated that it believes this area to be a major growth opportunity. This technology has the potential to be applied in a number of areas such as orthopaedics, dermatology, ophthalmology and cardiology.
Valuation: Increased slightly to $70m
Our rNPV-based valuation has increased to $70m/54.2c per share (NIS248m or NIS1.92/share) from $66m/52c per share as we roll our model forward by one quarter and apply an updated Q1 cash position of $1.24m. We continue to model illustrative long-term debt of NIS16m in 2017. We note the funding requirement in 2017 and that the company has indicated it has enough funds into Q317. Potential catalysts for the stock in our opinion include finding a partner or raising additional funding to develop its bone void filler and/or additional applications of its technology such as BioInk for 3D printing of organs and sales traction in Europe.
Exhibit 1: Financial summary
NIS'000s |
2014 |
2015 |
2016 |
2017e |
2018e |
||
Year end 31 Dec |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
|||||||
Revenue |
|
|
0 |
0 |
292 |
1,260.57 |
2,948.78 |
Cost of Sales |
0 |
0 |
0 |
(630) |
(1,474) |
||
Gross Profit |
0 |
0 |
292 |
630 |
1,474 |
||
R&D expenses, net |
(9,734) |
(11,864) |
(16,789) |
(13,431) |
(15,446) |
||
SG&A expenses |
(3,906) |
(6,950) |
(11,048) |
(3,535) |
(3,889) |
||
EBITDA |
|
|
(12,838) |
(18,026) |
(27,023) |
(15,535) |
(17,150) |
Operating Profit (before GW and except) |
|
(13,640) |
(18,814) |
(27,545) |
(16,336) |
(17,860) |
|
Intangible Amortisation |
0 |
0 |
0 |
0 |
0 |
||
Exceptionals |
0 |
0 |
0 |
0 |
0 |
||
Operating Profit |
(13,640) |
(18,814) |
(27,545) |
(16,336) |
(17,860) |
||
Other |
0 |
0 |
0 |
0 |
0 |
||
Net Interest |
617 |
164 |
(348) |
20 |
76 |
||
Profit Before Tax (norm) |
|
|
(13,023) |
(18,650) |
(27,893) |
(16,316) |
(17,785) |
Profit Before Tax (FRS 3) |
|
|
(13,023) |
(18,650) |
(27,893) |
(16,316) |
(17,785) |
Tax |
0 |
0 |
0 |
0 |
0 |
||
Profit After Tax (norm) |
(13,023) |
(18,650) |
(27,893) |
(16,316) |
(17,785) |
||
Profit After Tax (FRS 3) |
(13,023) |
(18,650) |
(27,893) |
(16,316) |
(17,785) |
||
Average Number of Shares Outstanding (m) |
80.4 |
84.7 |
100.6 |
128.3 |
128.3 |
||
EPS - normalised (NIS) |
|
|
(16.19) |
(22.03) |
(27.72) |
(12.72) |
(13.86) |
EPS - FRS 3 (NIS) |
|
|
(16.19) |
(22.03) |
(27.72) |
(12.72) |
(13.86) |
Dividend per share (NIS) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
BALANCE SHEET |
|||||||
Fixed Assets |
|
|
4,348 |
4,971 |
6,364 |
5,907 |
5,782 |
Intangible Assets |
1,725 |
1,721 |
1,631 |
1,631 |
1,631 |
||
Tangible Assets |
2,007 |
2,612 |
4,008 |
3,551 |
3,426 |
||
Other |
616 |
638 |
725 |
725 |
725 |
||
Current Assets |
|
|
12,610 |
8,558 |
8,069 |
19,253 |
5,310 |
Stocks |
0 |
0 |
487 |
487 |
487 |
||
Debtors |
1,548 |
3,241 |
3,785 |
3,785 |
3,785 |
||
Cash |
11,062 |
5,317 |
3,797 |
14,981 |
1,038 |
||
Other |
0 |
0 |
0 |
0 |
0 |
||
Current Liabilities |
|
|
(2,647) |
(3,750) |
(6,806) |
(6,806) |
(6,806) |
Creditors |
(1,642) |
(2,496) |
(5,189) |
(5,189) |
(5,189) |
||
Short term borrowings |
0 |
0 |
0 |
0 |
0 |
||
Short term leases |
0 |
0 |
0 |
0 |
0 |
||
Other |
(1,005) |
(1,254) |
(1,617) |
(1,617) |
(1,617) |
||
Long Term Liabilities |
|
|
0 |
0 |
(2,467) |
(18,467) |
(18,467) |
Long term borrowings |
0 |
0 |
(286) |
(16,286) |
(16,286) |
||
Long term leases |
0 |
0 |
0 |
0 |
0 |
||
Other long term liabilities |
0 |
0 |
(2,181) |
(2,181) |
(2,181) |
||
Net Assets |
|
|
14,311 |
9,779 |
5,160 |
(113) |
(14,181) |
CASH FLOW |
|||||||
Operating Cash Flow |
|
|
(12,958) |
(14,496) |
(19,384) |
(11,852) |
(13,282) |
Net Interest |
(35) |
(2) |
8 |
(20) |
(76) |
||
Tax |
35 |
1 |
0 |
0 |
0 |
||
Capex |
(336) |
(1,389) |
(492) |
(344) |
(585) |
||
Acquisitions/disposals |
0 |
0 |
0 |
0 |
0 |
||
Financing |
0 |
10,010 |
18,505 |
7,400 |
0 |
||
Dividends |
0 |
0 |
0 |
0 |
0 |
||
Other |
(16) |
27 |
(286) |
0 |
0 |
||
Net Cash Flow |
(13,310) |
(5,849) |
(1,649) |
(4,816) |
(13,944) |
||
Opening net debt/(cash) |
|
|
(23,777) |
(11,062) |
(5,317) |
(3,511) |
1,305 |
HP finance leases initiated |
0 |
0 |
0 |
0 |
0 |
||
Other |
595 |
104 |
(157) |
0 |
0 |
||
Closing net debt/(cash) |
|
|
(11,062) |
(5,317) |
(3,511) |
1,305 |
15,248 |
Source: Company accounts, Edison Investment Research
|
|
Pointer Telocation (PNTR) has reported solid Q1 figures backed by strong 25% subscriber growth and 7% growth in per subscriber revenues. Boosted by operating leverage this translated into wider service margins and a 43% increase in operating profit. In coming quarters, as individual fleet vehicles are equipped with PNTR’s telematics, subscriber revenues from the FEMSA and NYC taxicab contracts should start to boost group revenues. We see Q117 as a good start to the year and, with management discussing similar contracts with other companies and exploring new acquisitions, more good news is likely to follow in the coming quarters. We have increased our multiple based valuation by 26% to $13.6 (NIS48.9) per share, while maintaining our DCF valuation at $14.9 (NIS53.6) per share.